Pfizer (PFE) Current Assets (2009 - 2026)

Pfizer has disclosed Current Assets across 18 years of filings, most recently posting $42.8 billion for Q1 2026.

• In Q1 2026, Current Assets fell 6.63% year-over-year to $42.8 billion; the TTM figure through Mar 2026 stood at $42.8 billion (down 6.63% YoY), while the FY2025 annual figure was $42.9 billion, down 14.81% from the prior year.
• Current Assets was little changed at $42.8 billion in Q1 2026, from $42.9 billion in the prior quarter.
• Over the last five years, Current Assets for PFE reached as high as $74.0 billion in Q4 2023 and fell as low as $5.9 billion in Q4 2022.
• The 5-year median for Current Assets is $45.9 billion (2025), against an average of $48.0 billion.
• Annual changes were most pronounced in 2023 — Current Assets jumped 1147.67% — and 2024, when it slumped 48.43%.
• A 5-year view of Current Assets shows it stood at $51.3 billion in 2022, then fell by 15.46% to $43.3 billion in 2023, then grew by 16.21% to $50.4 billion in 2024, then decreased by 14.81% to $42.9 billion in 2025, then declined by 0.18% to $42.8 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $42.8 billion, $42.9 billion, and $46.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.